Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation

被引：13
|
作者：
Fang, Wenfeng [1 ]
Huang, Yihua [1 ]
Gan, Jiadi [1 ]
Shao, Yang W. [2 ]
Zhang, Li [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
基金：
国家重点研发计划;
关键词：
D O I：
10.1016/j.jtho.2019.05.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：E220 / E221
页数：2
相关论文
共 50 条
  • [41] A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma
    He, S.
    Yu, G.
    Lin, Q.
    Zhang, J.
    Shen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S587 - S588
  • [42] Clinical Response to Osimertinib in a Patient with Metastatic NSCLC Harboring EGFR A763_Y764insFQEA Exon 20 Insertion Mutation: A Case Report
    Montenegro, G. Bravo
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S575 - S576
  • [43] Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation
    Liu, Zhenkun
    Li, Pengfei
    Wu, Qiang
    Zhou, Qinghua
    ASIAN JOURNAL OF SURGERY, 2024, 47 (04) : 1851 - 1852
  • [44] pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M
    Ohashi, Kadoaki
    Kudo, Kenichiro
    Ichihara, Eiki
    Kayatani, Hiroe
    Higo, Hisao
    Kato, Yuka
    Kurata, Yasuko
    Minami, Daisuke
    Ninomiya, Takashi
    Kubo, Toshio
    Hotta, Katsuyuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2016, 76
  • [45] A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites
    Gu, Linping
    Zhao, Yi
    Wen, Fengcai
    Zhang, Ding
    Cai, Jinping
    Chen, Zhiwei
    ANTI-CANCER DRUGS, 2023, 34 (08) : 949 - 953
  • [46] BioCartis Idylla Testing for EGFR Mutations in Lung Adenocarcinoma Reveals Low Clinical Sensitivity for Detecting Exon 20 Insertion Alterations
    Zhong, E.
    Velu, P.
    Cong, L.
    Serrano, L.
    Solomon, J.
    Rennert, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S95 - S95
  • [47] Response to crizotinib and gefitinib in a lung adenocarcinoma patient harboring a concurrent EGFR exon 21 mutation and an ALK rearrangement.
    Bien-Willner, Gabriel Alejandro
    Yang, Dong
    McCanless, Christopher M.
    Mambo, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
    Zhao, Nan
    Xin, Hua
    Qin, Changjuan
    Li, Zhiqi
    Sun, Hongbin
    MEDICINE, 2022, 101 (49) : E31875
  • [49] Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib
    Kunimasa, Kei
    Nishino, Kazumi
    Kukita, Yoji
    Matsumoto, Shingo
    Kawachi, Hayato
    Kawamura, Takahisa
    Inoue, Takako
    Tamiya, Motohiro
    Honma, Keiichiro
    Sugimoto, Naotoshi
    Yamasaki, Tomoyuki
    Imamura, Fumio
    Goto, Koichi
    Kumagai, Toru
    CANCER GENETICS, 2021, 256 : 57 - 61
  • [50] A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in Exon 20 of EGFR
    Uramoto, Hidetaka
    Uchiumi, Takeshi
    Izumi, Hiroto
    Kohno, Kimitcishi
    Oyama, Tsunehiro
    Sugi, Kenji
    Yasumoto, Kosei
    ANTICANCER RESEARCH, 2007, 27 (4B) : 2297 - 2303
12345